As gene therapy emerges in the biotech industry, one analyst explains why it could be the next billion dollar industry.» Read More
Sanofi launched an inhalable insulin in the U.S. in a potential boost for its flagging diabetes drug sales and for patient quality of life.
A trial of an Ebola drug has been halted because of a sharp decline in patients with the disease in Liberia, the NYT reports.
CNBC's Meg Tirrell, has the latest details on the White House summit with medical researchers.
John Schroer, Allianz portfolio manager, shares his thoughts on precision medicine, and reveals his top biotech stock picks.
Brent Saunders, Actavis CEO, discusses how Actavis is leading the way in growth pharma and talks about its M&A strategy.
Robert Hugin, Celgene chairman & CEO, discusses his company's efforts to fight cancer and discusses promising drugs in the pipeline.
President Obama will dedicate $215 million in his budget request to a program that will target the underlying cause of disease.
John Lechleiter, Eli Lilly CEO, runs through the quarterly numbers and provides insight to products coming off patents, R&D, and new Alzheimer's drugs in the pipeline.
Fred Hassan, Warburg Pincus Partner, talks about the way information technology is changing the face of modern medicine and transforming the health care industry.
CNBC's Meg Tirrell has details on the meeting today between President Obama and drugmakers to discuss how to improve health and treat disease.
Two new studies discuss turning stem cells into hair cells and transplanting them onto bald spots.
The sheer volume and pace of biotech offerings are causing some to question whether the sector is nearing the end of its years of buoyancy.
Researchers found that feeding a group of children a form of beneficial bacteria helped them overcome a potentially fatal food allergy.
Cathrin Petty, co-head of EMEA healthcare at JP Morgan, says the U.K. has the capacity to be a successful market for life sciences, and the year ahead for healthcare IPOs looks strong.
George Freeman MP, minister of life sciences in the U.K., says there's been a "resurgence" for life sciences and healthcare investment.
Steve Harris, CEO of Circassia, says his company is combating allergies by tackling how they affect people's immune systems, rather than simply making products that provide "symptomatic relief".
The heads of research at several large drugmakers have received mysterious invitations to the White House for a meeting Friday morning.
Bristol-Myers Squibb reported higher-than-expected earnings, helped by strong sales of its hepatitis C drugs and its Eliquis blood clot preventer.
Pfizer reported stronger-than-expected quarterly results as sales of vaccines and cancer drugs increased.
Cole Smead, portfolio manager at Smead Capital Management, discusses the strong U.S. dollar and how it will affect sectors like pharmaceuticals.
Get the best of CNBC in your inbox